Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

Cencora-Kite Agreement Signals CGT Commercialization Shift

AI-generated analysis

🀝 Cencora has entered an agreement with Kite to support US distribution of Yescarta and Tecartus CAR T-cell therapies.

πŸ₯ The collaboration aims to expand access at authorized treatment centers by leveraging Cencora's distribution infrastructure.

πŸ“‰ A key goal is reducing administrative burdens and operational friction for community oncology practices and health systems.

🧬 CAR T-cell therapies are autologous treatments requiring precise coordination between treatment centers, manufacturers, and distributors.

⏱️ A January 2026 analysis found that 65% of community oncologists reported patients deteriorate before CAR T administration due to delays.

πŸš— Major obstacles to timely CAR T evaluation include travel distance, affordability, and prior authorization delays identified in a national survey.

πŸ“¦ Cencora's role includes managing order processes and supporting seamless experiences across new and existing sites in Kite's network.

πŸ’Ό Melissa Lattanzi of Cencora stated the partnership advances Kite's goal to bring therapies closer to patients' homes.

πŸ—£οΈ Christophe Griolet of Kite emphasized that Cencora's expertise will reduce provider barriers and meet patients where they are.

πŸ“Š Industry panelists at the 2026 Asembia summit questioned if current distribution models are ready for higher CGT volumes.

πŸ’° Cencora is executing a $1 billion infrastructure investment through 2030 to support complex therapy capabilities.

🏭 This investment includes a planned 530,000 square-foot national distribution center in Ohio with advanced automation and AI.

❄️ The new facility features expanded cold-chain capacity essential for storing sensitive cell therapies.

πŸ”„ The agreement signals a shift where specialty distributors play a central role in reducing institutional friction for patients.

πŸ† As CAR T-cell therapy expands, the ability to absorb administrative complexity at the distributor level will become a competitive differentiator.

Risk Factors
  • Industry panelists at the 2026 Asembia specialty pharmacy summit questioned whether existing distribution and payment models are ready for higher volumes anticipated with broader CGT adoption.
  • A January 2026 analysis reported that 65% of community oncologists noted patients deteriorate before CAR T administration, with payer approval timelines cited as a rate-limiting factor.
  • A national survey identified travel distance, ability to travel for evaluation, caregiver requirements, affordability, and prior authorization delays as the top five obstacles to timely CAR T evaluation.
Full Analysis
Cencora has entered into an agreement with Kite Pharma to support the US distribution of its two FDA-approved CAR T-cell therapies, Yescarta and Tecartus. The collaboration aims to reduce administrative burdens and expand access to these treatments at authorized treatment centers as Kite expands its network. Cencora will leverage its distribution infrastructure and services to facilitate efficient access and minimize operational friction for community oncology practices and health systems administering the therapies. The agreement covers both new and existing sites within Kite's treatment center network, with a focus on streamlining order management and supporting a seamless experience across health systems as the network grows. Melissa Lattanzi, vice president of emerging therapies at Cencora, highlighted that cell therapies are individualized treatments requiring precise coordination between treatment centers, manufacturers, and distribution networks to ensure patient outcomes are not compromised by timing issues. This partnership comes amid industry concerns about whether existing distribution models can handle higher volumes anticipated with broader adoption of cell and gene therapies. Cencora is investing $1 billion in infrastructure through 2030, including a new national distribution center in Ohio with advanced automation and cold-chain capacity. Christophe Griolet, US vice president at Kite, emphasized that the goal is to ensure every appropriate patient can access and benefit from these treatments by reducing provider barriers. The Cencora-Kite agreement signals a shift in how cell and gene therapies are commercialized, where specialty distributors play a central role in reducing institutional friction between treatment availability and patient access. As CAR T-cell therapy expands into more community settings, the ability to absorb administrative complexity at the distributor level will become a competitive differentiator for manufacturers choosing commercial partners.